AB-Biotics launches Neurofarmagen® genetic test on Italian market
The Catalan biotechnology firm has reached an agreement with FB Health
AB-Biotics, traded on the Alternative Stock Market (MAB), has signed an agreement with FB Health to market the Neurofarmagen® genetic test in Italy.
FB Health, which specializes in neurology and was founded by Dr. Francesco Bellini (who also founded BioChem Pharma), has launched Neurofarmagen® on the Italian market this month and will present it at the National Congress of the Italian Society of Psychopathology (SOPSI) in February.
The genetic test was developed by AB-Biotics and helps identify the best medication for each neuropsychiatric patient on an individual basis, using DNA from a saliva sample. A study with patients suffering from depression, psychotic disorders, anxiety and bipolar disorders showed that following the treatment recommendations of Neurofarmagen® cuts the number of non-stabilized patients nearly in half and thus doubles the number of patients that can stabilize the symptoms of their disease.
Italy is the second European country where Neurofarmagen® is being marketed, also available in Spain directly from AB-Biotics, in Brazil through GlaxoSmithKline, and in Mexico through Scienta Farma. The test is expected to launch in other countries before the end of the year.
More information is available in the press release.